A First-in-human, Multicenter Dose Escalation and Multiple Cohort Expansion Phase 1a/b Study to Investigate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ADCX-020 in Participants With Locally Advanced or Metastatic Solid Tumors
Latest Information Update: 15 Jun 2026
At a glance
- Drugs ADCX 020 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Adcytherix
Most Recent Events
- 31 Mar 2026 According to Adcytherix media release, first patient dosed in this trial.
- 17 Feb 2026 Status changed from not yet recruiting to recruiting.
- 20 Nov 2025 Status changed from planning to not yet recruiting.